Siga Technologies (SIGA) Cash from Financing Activities (2010 - 2025)
Siga Technologies' (SIGA) quarterly Cash from Financing Activities came in at -$403480.0 in Q3 2025, down 47.18% on a YoY basis from -$763943.4 in Q3 2024, and up 99.06% quarter-over-quarter from -$42.9 million in Q2 2025.
Analysis
Siga Technologies (SIGA) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Cash from Financing Activities for 16 consecutive years, with -$403480.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Cash from Financing Activities fell 47.18% year-over-year to -$403480.0; the trailing twelve-month figure through Sep 2025 stood at -$43.6 million (down 0.74% YoY), and the FY2024 full-year result was -$43.5 million, changed 0.1% from the prior year.
- Cash from Financing Activities grew to -$403480.0 in Q3 2025 per SIGA's latest filing, from -$42.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$158980.0 in Q1 2024 and bottomed at -$42.9 million in Q2 2025.
- Historically, Cash from Financing Activities has averaged -$12.7 million across 5 years, with a median of -$6.6 million in 2021.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 453.31% in 2022, then surged 97.9% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$5.8 million in 2021, then soared by 50.45% to -$2.9 million in 2022, then plunged by 1157.24% to -$35.9 million in 2023, then jumped by 99.55% to -$161756.0 in 2024, then slumped by 149.44% to -$403480.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$403480.0, -$42.9 million, and -$166193.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -3.66 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -2.10 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 2.42 Bn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 65.46 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 122.40 Mn |
| 10 | Siga Technologies | 235.60 Mn | 80.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -403,480.00 |
| Jun 30, 2025 | -42.89 Mn |
| Mar 31, 2025 | -166,193.00 |
| Dec 31, 2024 | -161,756.00 |
| Sep 30, 2024 | -274,132.00 |
| Jun 30, 2024 | -42.87 Mn |
| Mar 31, 2024 | -158,980.00 |
| Jun 30, 2023 | -35.87 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Dec 31, 2022 | -2.85 Mn |
| Jun 30, 2022 | -36.52 Mn |
| Mar 31, 2022 | -6.59 Mn |
| Dec 31, 2021 | -5.76 Mn |
| Sep 30, 2021 | -7.30 Mn |
| Jun 30, 2021 | -6.60 Mn |
| Mar 31, 2021 | -6.54 Mn |
| Dec 31, 2020 | -6.72 Mn |
| Sep 30, 2020 | -5.74 Mn |
| Jun 30, 2020 | -15.22 Mn |
| Mar 31, 2020 | -86.92 Mn |